SMAD3 and glioblastoma: GBM cells can undergo transitions in molecular subtype in response to chemotherapy or radiotherapy and according to the microenvironment of the tumor, which may lead to differences in effects between in vitro and in vivo experiments using HIF-1α and Smad3 inhibitors.